Yang, Zhengyu

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 684

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 306

Global estimates of daily ambient fine particulate matter concentrations and unequal spatiotemporal distribution of population exposure: A machine learning modelling study

Yu, W., Ye, T., Zhang, Y., Xu, R., Lei, Y., Chen, Z., Yang, Z., Zhang, Y., Song, J., Yue, X., et al. (2023) · The Lancet Planetary Health

Air Quality and Health ImpactsAir Quality Monitoring and Forecasting

Cited by 215

Effects of tirzepatide versus insulin glargine on cystatin C-based kidney function: a SURPASS-4 post hoc analysis

Heerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Wilson, J. M., Hemmingway, A., Cherney, D. Z. I., et al. (2023) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 53

Billions of people exposed to increasing heat but decreasing greenness from 2000 to 2022

Ye, T., Xu, R., Huang, W., Yang, Z., Yu, P., Yu, W., Liu, Y., Wu, Y., Wen, B., Zhang, Y., et al. (2025) · The Innovation

Urban Heat Island MitigationClimate Change and Health Impacts

Cited by 13

Abstract 16779: Tirzepatide Reduces High-Sensitivity C-reactive Protein in Patients With Type 2 Diabetes and High Cardiovascular Risk: A Post Hoc Analysis of the SURPASS-4 Trial

Bhatt, D. L., Wilson, J. M., Wiese, R. J., Yang, Z., Duffin, K. L., & Pavo, I. (2023) · Circulation

Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases

Cited by 5

Effect of Tirzepatide on Kidney Function in People with Excess Body Weight: A Post Hoc Analysis of the SURMOUNT-1 Trial: FR-OR47

Heerspink, H. J., Friedman, A. N., Bjornstad, P., Raalte, D. H. V., Yang, Z., Stefanski, A., Chigutsa, F. B., Turfanda, I., Bunck, M., & de Oliveira, C. P. (2023) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 3